article thumbnail

Novartis Reclaims Anthos, Reenters Factor XI Race

CardiacWire

Anthos LILAC trial is focused on preventing stroke and systemic embolism in AFib patients, while ASTER and MAGNOLIA aim to use abelacimab to address VTE and GI cancer. Novartis abelacimab efforts will now take a unique clinical approach since the Anthos-designed phase 3 trials focus on more than just ischemic stroke.

AFIB 102
article thumbnail

Amulet’s Slight Edge over Watchman for LAAO

CardiacWire

LAAO (left atrial appendage occlusion) devices help prevent stroke in patients with AFib by sealing off the left atrial appendage where blood clots can form. Devices like the Amulet and Watchman provide an alternative to anticoagulants for AFib stroke prevention in patients who cannot take blood thinners. for Amulet vs. 20.0%

AFIB 52
article thumbnail

Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC

DAIC

Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.

AFIB 52
article thumbnail

Abelacimab Stops Bleeding, But Stroke Impact Uncertain

CardiacWire

Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. year follow-up. per 100 person-years vs. 0.83). per 100 person-year.

Stroke 59
article thumbnail

ENBALV: Edoxaban vs. Warfarin Following Bioprosthetic Valve Surgery in Patients With Non-Valvular AFib

American College of Cardiology

Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.

AFIB 48
article thumbnail

OCEANIC-AF: Asundexian vs. Apixaban in Patients With AFib

American College of Cardiology

Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial fibrillation (AFib) who were at high risk for stroke, based on findings from the OCEANIC-AF trial presented at ESC Congress 2024 in London and simultaneously published in The New England Journal (..)

AFIB 41
article thumbnail

InterAtrial Block

EMS 12-Lead

Examples of cardio embolic stroke etiology include: 1. Atrial Fibrillation 2. Cardiomyopathy with mural thrombus 3. Patent Foramen Ovale 4. Severe calcific Aortic (valve) Stenosis 5. Mechanical prosthetic valve Severe carotid artery stenosis is also implicated in embolic stroke. AFib can come and go.

AFIB 59